Shares of Renalytix Plc (LON:RENX – Get Free Report) rose 14.2% during trading on Monday . The stock traded as high as GBX 2.80 and last traded at GBX 2.65. Approximately 7,356,022 shares were traded during trading, an increase of 719% from the average daily volume of 897,943 shares. The stock had previously closed at GBX 2.32.
Renalytix Stock Performance
The company has a debt-to-equity ratio of -118.57, a current ratio of 1.21 and a quick ratio of 2.42. The stock has a market capitalization of £13.11 million, a P/E ratio of -0.75 and a beta of 1.79. The company has a fifty day moving average of GBX 1.87 and a two-hundred day moving average of GBX 3.32.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
See Also
- Five stocks we like better than Renalytix
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
